Contents

ALTAIR

February 3, 2020

Clinical Trial

Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR : A Randomized Controlled Trial.

Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y.

Adv Ther. 2020 Mar;37(3):1173-1187.
Full text | Metrics.

Main finding: Intravitreal Aflibercept administered using two different treat-and-extend regimens for CNV secondary to AMD improved functional and anatomic outcomes at week 52 and outcomes were maintained to week 96.

 

  • Purpose: To evaluate efficacy and safety of intravitreal aflibercept treat-and-extend dosing regimens in treatment-naïve patients with exudative age-related macular degeneration AMD
  • Study type: Randomized controlled trial
  • Condition: CNV secondary to AMD

Participants: ≥50yo, active CNV secondary to AMD, BCVA 20/40-20/320

 

  • n=246

 

Intervention:

 

Group 1: Intravitreal Aflibercept 2mg, 3 initial mnnthly doses then treat and extend with 2-week adjustments
Group 2: Intravitreal Aflibercept 2mg, 3 initial mnnthly doses then treat and extend with 4-week adjustment

Outcomes Time AFLI 2 week interval AFLI 4 week interval
Mean no. of injections 52 weeks 7.2 6.9
96 weeks 10.4 10.4
Mean last injection interval ( 96 weeks 10.7 11.8
Mean VA change( letters) 96 weeks +7.6 +6.1

Share This Article :

Updated on January 24th, 2022

Source Archive

© 2024 - sourceshed